{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T17:24:16Z","timestamp":1767979456449,"version":"3.49.0"},"reference-count":38,"publisher":"Termedia Sp. z.o.o.","issue":"2","license":[{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-sa\/4.0\/"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"am","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-sa\/4.0\/"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-sa\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cent Eur J Immunol"],"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>The aim of the study was to find an ideal index reflecting inflammation and fibrosis for patients after antiviral treatment, and compare it with imaging examination (liver stiffness measurement \u2013 LSM) and traditional liver fibrosis models (APRI and FIB-4).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Material and methods<\/jats:title>\n                    <jats:p>A total of 77 chronic hepatitis B (CHB) patients who achieved a sustained virological response (SVR) after entecavir (ETV) treatment were included, and the changes of various clinical indicators before and after treatment were compared.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>After 78 weeks of ETV treatment, WBC and PLT of 77 patients were significantly increased, while ALT, AST and total bilirubin were significantly decreased (&lt;i&gt;p&lt;\/i&gt; &lt; 0.05). There was no significant difference in serum creatinine (Cr) or blood urea nitrogen (BUN) compared to the values before treatment (&lt;i&gt;p&lt;\/i&gt; &gt; 0.05). The three non-invasive liver fibrosis indexes, namely, LSM, APRI and FIB-4, were significantly decreased in 77 patients compared to the values before treatment (&lt;i&gt;p&lt;\/i&gt; &lt; 0.001).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Acoustic radiation force impulse (ARFI), fibrosis-4 (FIB-4), aspartate aminotransferase-to-platelet ratio index (APRI) have a high consistency with the grading of liver fibrosis, and can be used to evaluate the severity of liver fibrosis. Among them, ARFI has good diagnostic value for the classification of different degrees of liver fibrosis and the best diagnostic accuracy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.5114\/ceji.2023.127621","type":"journal-article","created":{"date-parts":[[2023,6,13]],"date-time":"2023-06-13T05:13:10Z","timestamp":1686633190000},"page":"126-134","source":"Crossref","is-referenced-by-count":1,"title":["Efficacy evaluation of\u00a0direct antiviral drugs against hepatitis B virus in improving the\u00a0degree of\u00a0liver fibrosis"],"prefix":"10.5114","volume":"48","author":[{"given":"Liang","family":"Miao","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lihua","family":"Cao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guiqiang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"3061","published-online":{"date-parts":[[2023,6,1]]},"reference":[{"key":"ref-1537003","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/S2468-1253(19)30119-0","article-title":"A global scientific strategy to cure hepatitis B","volume":"4","author":"Revill PA","year":"2019","unstructured":"Revill PA, Chisari FV, Block JM, et al. (2019): A global scientific strategy to cure hepatitis B. Lancet Gastroenterol Hepatol 4: 545-558.","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"ref-1537004","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1016\/j.jfma.2021.09.002","article-title":"Serum cytokine\/chemokine profiles predict hepatitis B reactivation in HBV\/HCV co-infected subjects receiving direct-acting antiviral agents","volume":"121","author":"Huang SC","year":"2022","unstructured":"Huang SC, Cheng PN, Liu CH, et al. (2022): Serum cytokine\/chemokine profiles predict hepatitis B reactivation in HBV\/HCV co-infected subjects receiving direct-acting antiviral agents. J Formos Med Assoc 121: 920-929.","journal-title":"J Formos Med Assoc"},{"key":"ref-1537005","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.cgh.2016.06.023","article-title":"Hepatitis due to reactivation of hepatitis B virus in endemic areas among patients with hepatitis C treated with direct-acting antiviral agents","volume":"15","author":"Wang C","year":"2017","unstructured":"Wang C, Ji D, Chen J, et al. (2017): Hepatitis due to reactivation of hepatitis B virus in endemic areas among patients with hepatitis C treated with direct-acting antiviral agents. Clin Gastroenterol Hepatol 15: 132-136.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"ref-1537006","first-page":"9","article-title":"Guidelines for the prevention and treatment of chronic hepatitis B (2019 edition)","volume":"23","author":"Wang GQ","year":"2020","unstructured":"Wang GQ, Duan ZP, Wang FS, et al. (2020): Guidelines for the prevention and treatment of chronic hepatitis B (2019 edition). J Pract Hepatol 23: 9-32.","journal-title":"J Pract Hepatol"},{"key":"ref-1537007","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.1111\/hepr.12919","article-title":"Frequency of, and factors associated with, hepatitis B virus reactivation in hepatitis C patients treated with all-oral direct-acting antivirals: Analysis of a Japanese prospective cohort","volume":"47","author":"Doi A","year":"2017","unstructured":"Doi A, Sakamori R, Tahata Y, et al. (2017): Frequency of, and factors associated with, hepatitis B virus reactivation in hepatitis C patients treated with all-oral direct-acting antivirals: Analysis of a Japanese prospective cohort. Hepatol Res 47: 1438-1444.","journal-title":"Hepatol Res"},{"key":"ref-1537008","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1111\/jgh.14067","article-title":"Hepatitis C virus clearance by direct-acting antiviral treatments and impact on insulin resistance in chronic hepatitis C patients","volume":"33","author":"Adinolfi LE","year":"2018","unstructured":"Adinolfi LE, Nevola R, Guerrera B, et al. (2018): Hepatitis C virus clearance by direct-acting antiviral treatments and impact on insulin resistance in chronic hepatitis C patients. J Gastroenterol Hepatol 33: 1379-1382.","journal-title":"J Gastroenterol Hepatol"},{"key":"ref-1537009","doi-asserted-by":"crossref","first-page":"792","DOI":"10.7326\/M17-0377","article-title":"Hepatitis B virus reactivation associated with direct-acting antiviral therapy for chronic hepatitis C virus: a review of cases reported to the US Food and Drug Administration Adverse Event Reporting System","volume":"166","author":"Bersoff-Matcha SJ","year":"2017","unstructured":"Bersoff-Matcha SJ, Cao K, Jason M, et al. (2017): Hepatitis B virus reactivation associated with direct-acting antiviral therapy for chronic hepatitis C virus: a review of cases reported to the US Food and Drug Administration Adverse Event Reporting System. Ann Intern Med 166: 792-798.","journal-title":"Ann Intern Med"},{"key":"ref-1537010","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/j.gtc.2011.06.010","article-title":"Noninvasive tools to assess hepatic fibrosis: ready for prime time?","volume":"40","author":"Schmeltzer PA","year":"2011","unstructured":"Schmeltzer PA, Talwalkar JA (2011): Noninvasive tools to assess hepatic fibrosis: ready for prime time? Gastroenterol Clin North Am 40: 507-521.","journal-title":"Gastroenterol Clin North Am"},{"key":"ref-1537011","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s12072-015-9675-4","article-title":"Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update","volume":"10","author":"Sarin SK","year":"2016","unstructured":"Sarin SK, Kumar M, Lau GK, et al. (2016): Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update. Hepatol Int 10: 1-98.","journal-title":"Hepatol Int"},{"key":"ref-1537012","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.jhep.2012.02.010","article-title":"EASL clinical practice guidelines: Management of chronic hepatitis B virus infection","volume":"57","author":"European Association For The Study Of The Liver","year":"2012","unstructured":"European Association For The Study Of The Liver (2012): EASL clinical practice guidelines: Management of chronic hepatitis B virus infection. J Hepatol 57: 167-185.","journal-title":"J Hepatol"},{"key":"ref-1537013","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1002\/hep.28156","article-title":"AASLD guidelines for treatment of chronic hepatitis B","volume":"63","author":"Terrault NA","year":"2016","unstructured":"Terrault NA, Bzowej NH, Chang KM, et al. (2016): AASLD guidelines for treatment of chronic hepatitis B. Hepatology 63: 261-283.","journal-title":"Hepatology"},{"key":"ref-1537014","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1042\/CS20060242","article-title":"Liver fibrosis: cellular mechanisms of progression and resolution","volume":"112","author":"Henderson NC","year":"2007","unstructured":". Henderson NC, Iredale JP (2007): Liver fibrosis: cellular mechanisms of progression and resolution. Clin Sci 112: 265-280.","journal-title":"Clin Sci"},{"key":"ref-1537015","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1111\/jvh.13233","article-title":"Hepatitis C virus testing, liver disease assessment and treatment uptake among people who inject drugs pre-and post-universal access to direct-acting antiviral treatment in Australia: The LiveRLife study","volume":"27","author":"Bajis S","year":"2020","unstructured":"Bajis S, Grebely J, Hajarizadeh B, et al. (2020): Hepatitis C virus testing, liver disease assessment and treatment uptake among people who inject drugs pre-and post-universal access to direct-acting antiviral treatment in Australia: The LiveRLife study. J Viral Hepat 27: 281-293.","journal-title":"J Viral Hepat"},{"key":"ref-1537016","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1111\/j.1365-2036.2007.03252.x","article-title":"Variability of the area under the receiver operating characteristic curves in the diagnostic evaluation of liver fibrosis markers: impact of biopsy length and fragmentation","volume":"25","author":"Poynard T","year":"2007","unstructured":"Poynard T, Halfon P, Castera L, et al. (2007): Variability of the area under the receiver operating characteristic curves in the diagnostic evaluation of liver fibrosis markers: impact of biopsy length and fragmentation. Aliment Pharmacol Ther 25: 733-739.","journal-title":"Aliment Pharmacol Ther"},{"key":"ref-1537017","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1016\/j.hep.2003.09.022","article-title":"Sampling variability of liver fibrosis in chronic hepatitis C","volume":"38","author":"Bedossa P","year":"2003","unstructured":"Bedossa P, Dargere D, Paradis V (2003): Sampling variability of liver fibrosis in chronic hepatitis C. Hepatology 38: 1449-1457.","journal-title":"Hepatology"},{"key":"ref-1537018","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1111\/j.1478-3231.2004.0957.x","article-title":"Quantitative assessment of fibrosis in liver biopsies from patients with chronic hepatitis B","volume":"24","author":"Hui AY","year":"2004","unstructured":"Hui AY, Liew CT, Go MY, et al. (2004): Quantitative assessment of fibrosis in liver biopsies from patients with chronic hepatitis B. Liver Int 24: 611-618.","journal-title":"Liver Int"},{"key":"ref-1537019","doi-asserted-by":"crossref","first-page":"2614","DOI":"10.1111\/j.1572-0241.2002.06038.x","article-title":"Sampling error and intraobserver variation in liver biopsy in patients with chronic HCV infection","volume":"97","author":"Regev A","year":"2002","unstructured":"Regev A, Berho M, Jeffers LJ, et al. (2002): Sampling error and intraobserver variation in liver biopsy in patients with chronic HCV infection. Am J Gastroenterol 97: 2614-2618.","journal-title":"Am J Gastroenterol"},{"key":"ref-1537020","volume-title":"Copyright (c) World Health Organization 2015","author":"WHO Guidelines Approved by the Guidelines Review Committee","year":"2015","unstructured":"WHO Guidelines Approved by the Guidelines Review Committee. Guidelines for the Prevention, Care and Treatment of Persons with Chronic Hepatitis B Infection. Geneva: World Health Organization. Copyright (c) World Health Organization 2015, 2015."},{"key":"ref-1537021","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1053\/jhep.2003.50346","article-title":"A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C","volume":"38","author":"Wai CT","year":"2003","unstructured":"Wai CT, Greenson JK, Fontana RJ, et al. (2003): A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology 38: 518-526.","journal-title":"Hepatology"},{"key":"ref-1537022","doi-asserted-by":"crossref","first-page":"1704","DOI":"10.1053\/j.gastro.2004.08.052","article-title":"Serum markers detect the presence of liver fibrosis: a cohort study","volume":"127","author":"Rosenberg WM","year":"2004","unstructured":"Rosenberg WM, Voelker M, Thiel R, et al. (2004): Serum markers detect the presence of liver fibrosis: a cohort study. Gastroenterology 127: 1704-1713.","journal-title":"Gastroenterology"},{"key":"ref-1537023","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1016\/j.jhep.2005.10.019","article-title":"Performance of serum marker panels for liver fibrosis in chronic hepatitis C","volume":"44","author":"Parkes J","year":"2006","unstructured":"Parkes J, Guha IN, Roderick P, Rosenberg W (2006): Performance of serum marker panels for liver fibrosis in chronic hepatitis C. J Hepatol 44: 462-474.","journal-title":"J Hepatol"},{"key":"ref-1537024","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.1002\/hep.24515","article-title":"Biomarkers of liver fibrosis: what lies beneath the receiver operating characteristic curve","volume":"54","author":"Guha IN","year":"2011","unstructured":"Guha IN, Myers RP, Patel K, Talwalkar JA (2011): Biomarkers of liver fibrosis: what lies beneath the receiver operating characteristic curve. Hepatology 54: 1454-1462.","journal-title":"Hepatology"},{"key":"ref-1537025","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1053\/j.gastro.2012.02.017","article-title":"Noninvasive methods to assess liver disease in patients with hepatitis B or C","volume":"142","author":"Castera L","year":"2012","unstructured":"Castera L (2012): Noninvasive methods to assess liver disease in patients with hepatitis B or C. Gastroenterology 142: 1293-1302.","journal-title":"Gastroenterology"},{"key":"ref-1537026","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1002\/hep.28280","article-title":"Antiviral therapy for chronic hepatitis B viral infection in adults: A systematic review and meta-analysis","volume":"63","author":"Lok AS","year":"2016","unstructured":"Lok AS, McMahon BJ, Brown RS, et al. (2016): Antiviral therapy for chronic hepatitis B viral infection in adults: A systematic review and meta-analysis. Hepatology 63: 284-306.","journal-title":"Hepatology"},{"key":"ref-1537027","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/S2468-1253(20)30307-1","article-title":"Estimating the proportion of people with chronic hepatitis B virus infection eligible for hepatitis B antiviral treatment worldwide: a systematic review and meta-analysis","volume":"6","author":"Tan M","year":"2021","unstructured":"Tan M, Bhadoria AS, Cui F, et al. (2021): Estimating the proportion of people with chronic hepatitis B virus infection eligible for hepatitis B antiviral treatment worldwide: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol 6: 106-119.","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"ref-1537028","doi-asserted-by":"crossref","first-page":"2395","DOI":"10.1002\/hep.32018","article-title":"Comparison of HBV RNA and hepatitis B core related antigen with conventional HBV markers among untreated adults with chronic hepatitis B in North America","volume":"74","author":"Ghany MG","year":"2021","unstructured":"Ghany MG, King WC, Lisker-Melman M, et al. (2021): Comparison of HBV RNA and hepatitis B core related antigen with conventional HBV markers among untreated adults with chronic hepatitis B in North America. Hepatology 74: 2395-2409.","journal-title":"Hepatology"},{"key":"ref-1537029","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1002\/hep.31026","article-title":"Pregenomic HBV RNA and hepatitis B core-related antigen predict outcomes in hepatitis B e antigen\u2013negative chronic hepatitis B patients suppressed on nucleos(t)ide analogue therapy","volume":"72","author":"Carey I","year":"2020","unstructured":"Carey I, Gersch J, Wang BO, et al. (2020): Pregenomic HBV RNA and hepatitis B core-related antigen predict outcomes in hepatitis B e antigen\u2013negative chronic hepatitis B patients suppressed on nucleos(t)ide analogue therapy. Hepatology 72: 42-57.","journal-title":"Hepatology"},{"key":"ref-1537030","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/j.jhep.2019.11.003","article-title":"Guidance for design and endpoints of clinical trials in chronic hepatitis B-Report from the 2019 EASL-AASLD HBV Treatment Endpoints Conference","volume":"72","author":"Cornberg M","year":"2020","unstructured":"Cornberg M, Lok ASF, Terrault NA, et al. (2020): Guidance for design and endpoints of clinical trials in chronic hepatitis B-Report from the 2019 EASL-AASLD HBV Treatment Endpoints Conference. J Hepatol 72: 539-557.","journal-title":"J Hepatol"},{"key":"ref-1537031","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1182\/blood-2018-04-848044","article-title":"Risk of HBV reactivation in patients with B-cell lymphomas receiving obinutuzumab or rituximab immunochemotherapy","volume":"133","author":"Kusumoto S","year":"2019","unstructured":"Kusumoto S, Arcaini L, Hong X, et al. (2019): Risk of HBV reactivation in patients with B-cell lymphomas receiving obinutuzumab or rituximab immunochemotherapy. Blood 133: 137-146.","journal-title":"Blood"},{"key":"ref-1537032","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1007\/s12072-020-10099-x","article-title":"Effect of combination treatment based on interferon and nucleos (t) ide analogues on functional cure of chronic hepatitis B: a systematic review and meta-analysis","volume":"14","author":"Liu J","year":"2020","unstructured":"Liu J, Wang T, Zhang W, et al. (2020): Effect of combination treatment based on interferon and nucleos (t) ide analogues on functional cure of chronic hepatitis B: a systematic review and meta-analysis. Hepatol Int 14: 958-972.","journal-title":"Hepatol Int"},{"key":"ref-1537033","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/j.cgh.2020.05.041","article-title":"Association between seroclearance of hepatitis B surface antigen and long-term clinical outcomes of patients with chronic hepatitis B virus infection: systematic review and meta-analysis","volume":"19","author":"Anderson RT","year":"2021","unstructured":"Anderson RT, Choi HSJ, Lenz O, et al. (2021): Association between seroclearance of hepatitis B surface antigen and long-term clinical outcomes of patients with chronic hepatitis B virus infection: systematic review and meta-analysis. Clin Gastroenterol Hepatol 19: 463-472.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"ref-1537034","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1097\/QAI.0000000000001996","article-title":"Factors associated with excess myocardial infarction risk in HIV-infected adults: a systematic review and meta-analysis","volume":"81","author":"Rao SG","year":"2019","unstructured":"Rao SG, Galaviz KI, Gay HC, et al. (2019): Factors associated with excess myocardial infarction risk in HIV-infected adults: a systematic review and meta-analysis. J Acquir Immune Defic Syndr 81: 224-230.","journal-title":"J Acquir Immune Defic Syndr"},{"key":"ref-1537035","doi-asserted-by":"crossref","first-page":"e00236","DOI":"10.14309\/ctg.0000000000000236","article-title":"Entecavir vs tenofovir in hepatocellular carcinoma prevention in chronic hepatitis B infection: a systematic review and meta-analysis","volume":"11","author":"Cheung KS","year":"2020","unstructured":"Cheung KS, Mak LY, Liu SH, et al. (2020): Entecavir vs tenofovir in hepatocellular carcinoma prevention in chronic hepatitis B infection: a systematic review and meta-analysis. Clin Transl Gastroenterol 11: e00236.","journal-title":"Clin Transl Gastroenterol"},{"key":"ref-1537036","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1111\/jvh.13452","article-title":"Risk factors for the development of hepatocellular carcinoma (HCC) in chronic hepatitis B virus (HBV) infection: a systematic review and meta-analysis","volume":"28","author":"Campbell C","year":"2021","unstructured":"Campbell C, Wang T, McNaughton AL, et al. (2021): Risk factors for the development of hepatocellular carcinoma (HCC) in chronic hepatitis B virus (HBV) infection: a systematic review and meta-analysis. J Viral Hepat 28: 493-507.","journal-title":"J Viral Hepat"},{"key":"ref-1537037","doi-asserted-by":"crossref","first-page":"76","DOI":"10.3904\/kjim.2018.465","article-title":"Role of tenofovir disoproxil fumarate in prevention of perinatal transmission of hepatitis B virus from mother to child: a systematic review and meta-analysis","volume":"36","author":"Lee YS","year":"2021","unstructured":"Lee YS, Lee HS, Kim JH, et al. (2021): Role of tenofovir disoproxil fumarate in prevention of perinatal transmission of hepatitis B virus from mother to child: a systematic review and meta-analysis. Korean J Intern Med 36: 76-85.","journal-title":"Korean J Intern Med"},{"key":"ref-1537038","doi-asserted-by":"crossref","first-page":"ofab289","DOI":"10.1093\/ofid\/ofab289","article-title":"A systematic review and meta-analysis of studies evaluating the effect of medication treatment for opioid use disorder on infectious disease outcomes","volume":"8","author":"McNamara KF","year":"2021","unstructured":"McNamara KF, Biondi BE, Hern\u00e1ndez-Ram\u00edrez RU, et al. (2021): A systematic review and meta-analysis of studies evaluating the effect of medication treatment for opioid use disorder on infectious disease outcomes. Open Forum Infect Dis 8: ofab289.","journal-title":"Open Forum Infect Dis"},{"key":"ref-1537039","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.idh.2018.02.006","article-title":"Hepatitis B virus and HIV coinfection among adults residing in Cameroon: A systematic review and meta-analysis of prevalence studies","volume":"23","author":"Bigna JJ","year":"2018","unstructured":"Bigna JJ, Nkeck JR, Ngouo A, et al. (2018): Hepatitis B virus and HIV coinfection among adults residing in Cameroon: A systematic review and meta-analysis of prevalence studies. Infect Dis Health 23: 170-178.","journal-title":"Infect Dis Health"},{"key":"ref-1537040","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1016\/S2468-1253(22)00201-1","article-title":"Prevalence of occult hepatitis B virus infection in adults: a systematic review and meta-analysis","volume":"7","author":"Im YR","year":"2022","unstructured":"Im YR, Jagdish R, Leith D, et al. (2022): Prevalence of occult hepatitis B virus infection in adults: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol 7: 932-942.","journal-title":"Lancet Gastroenterol Hepatol"}],"container-title":["Central European Journal of Immunology"],"original-title":[],"link":[{"URL":"https:\/\/ceji.termedia.pl\/pdf-163430-129608","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/ceji.termedia.pl\/pdf-163430-129608","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T08:31:10Z","timestamp":1767947470000},"score":1,"resource":{"primary":{"URL":"https:\/\/ceji.termedia.pl\/Efficacy-evaluation-of-direct-antiviral-drugs-against-hepatitis-B-virus-in-improving,163430,0,2.html"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,1]]},"references-count":38,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023]]}},"alternative-id":["163430"],"URL":"https:\/\/doi.org\/10.5114\/ceji.2023.127621","relation":{},"ISSN":["1426-3912","1644-4124"],"issn-type":[{"value":"1426-3912","type":"print"},{"value":"1644-4124","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,1]]}}}